FDA Grants Antibody-Drug Conjugate Breakthrough Designation in TNBC
Sacituzumab govitecan (IMMU-132) has received an FDA breakthrough therapy designation for the treatment of patients with triple-negative breast cancer following at least 2 treatments for metastatic disease.
Blinatumomab Improves Survival in Acute Lymphoblastic Leukemia
The phase III TOWER study has been halted after an independent panel determined that blinatumomab (Blincyto) improved overall survival versus standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
FDA Approves Single-Dose Fosaprepitant for CINV
The FDA approved single-dose fosaprepitant dimeglumine (Emend for injection) in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC), according to Merck, the developer of the drug.
World Cancer Day Aims to Unite Millions to Increase Awareness, Reduce Global Burden
With more than 8 million cancer deaths worldwide every year, the Union for International Cancer Control hopes to encourage both groups and individuals to reflect on how they can help reduce the global burden of cancer on February 4, World Cancer Day.
ASCO Selects Immunotherapy as "Cancer Advance of the Year"
ASCO has named immunotherapy, targeting agents that block PD-1/PD-L1 immune checkpoint across a vast array of tumor types, as its “Cancer Advance of the Year.”
Expert Hails Ixazomib Approval as “Huge Advance” in Multiple Myeloma
Philippe Moreau, MD, discusses the significance of ixazomib and the TOURMALINE-MM1 study, as well as the benefit of an oral regimen for the treatment of patients with relapsed multiple myeloma.
Osimertinib Approved in Europe for EGFR T790M-Mutant NSCLC
The European Commission has granted a conditional marketing authorization to osimertinib for patients with locally advanced or metastatic EGFR T790M mutation-positive non–small cell lung cancer, regardless of prior treatment with EGFR TKI.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.